Saxenda and Zepbound are different prescription injections: Saxenda contains liraglutide; Zepbound contains tirzepatide. Their approved uses overlap, but their receptor targets, administration and certain precautions differ. Neither brand name alone tells you which treatment fits your circumstances.
This adult-focused U.S. comparison uses the Saxenda prescribing information, revised February 2026, and Zepbound prescribing information, revised August 2026. Sources were checked October 3, 2026.
Saxenda availability update: Novo Nordisk announces that it will discontinue Saxenda, with final shipments to wholesalers planned for late January 2027. The company describes a strategic portfolio decision unrelated to safety or quality concerns. The notice does not establish your pharmacy's current stock. If you use or are considering Saxenda, ask your prescriber and pharmacist about continuity of treatment.
Saxenda vs Zepbound at a glance
| Detail | Saxenda | Zepbound |
|---|---|---|
| Active ingredient | Liraglutide | Tirzepatide |
| Drug class | GLP-1 receptor agonist | GIP and GLP-1 receptor agonist |
| Approved adult weight-management use | Weight reduction and long-term maintenance in the adult groups specified in its label | Weight reduction and long-term maintenance in adults with obesity, or overweight plus a weight-related condition |
| Other approved adult use | No obstructive sleep apnea indication | Moderate-to-severe obstructive sleep apnea in adults with obesity |
| Label administration frequency | Saxenda: “once daily” (section 2) | Zepbound: “once weekly” (section 2) |
| Route and presentations | Injection under the skin; single-patient-use pen | Injection under the skin; single-dose pens/vials, multi-dose vials and KwikPens |
| Safety discussion to bring to the visit | Thyroid warning, serious allergy, gastrointestinal risks and heart-rate monitoring | Thyroid warning, serious allergy, gastrointestinal risks and birth control pill precautions |
The table draws on the current labels and Saxenda’s Medication Guide; it is not a prescribing guide. For adult weight management, both labels address obesity, or overweight with at least one weight-related condition; your prescriber assesses eligibility under the current label. Both include nutrition and activity support. Saxenda also has a labeled use for certain pediatric patients aged 12 years and older with obesity and body weight greater than 60 kg. This article focuses on adult decisions and does not cover pediatric treatment.
Zepbound's separate FDA sleep apnea approval concerns a defined diagnosis and population. Trouble sleeping or snoring alone does not establish that indication. Ask your clinician which condition a proposed prescription is intended to treat.
Does the comparison identify a better medicine for you?
A receptor difference describes how a medicine acts; it does not settle an individual treatment decision. A personal discussion should connect anticipated benefit with your health priorities, previous treatment experience, tolerability and practical access.
Ask how your clinician will assess progress. The useful conversation may include daily function, ability to eat and drink comfortably, activity and the condition being treated, alongside weight. A trial average cannot promise your result, and percentages from separate studies should not become a head-to-head ranking.
For another product-identity question, see how Zepbound differs from Ozempic injection.
Which safety questions matter before treatment?
Contraindications: both labels exclude people with a personal or family history of medullary thyroid carcinoma, a specific thyroid cancer, or multiple endocrine neoplasia syndrome type 2, an inherited condition. They also exclude serious allergic reactions to the respective medicine or its ingredients. Their boxed warnings concern thyroid C-cell tumors observed in rodents; relevance to humans is unknown. This is not a blanket contraindication for every thyroid condition. See section 4 and the boxed warnings in the Saxenda and Zepbound labels.
Warnings and monitoring: nausea, vomiting, diarrhea and constipation can occur. The labels address severe gastrointestinal reactions, pancreatitis, gallbladder events and dehydration-related kidney injury; neither recommends use in severe gastroparesis, meaning severely delayed stomach emptying. Insulin or sulfonylureas can increase the concern for low blood sugar. Tell your clinician about diabetes medicines and planned anesthesia or sedation. See sections 5–7 of the Saxenda and Zepbound labels; the FDA Zepbound approval notice also describes these risks.
Pregnancy: discuss pregnancy plans before treatment. Both labels say to discontinue the medicine when pregnancy is recognized; contact your prescriber promptly if this occurs. This pregnancy information is separate from the contraindications above. See section 8.1 of the Saxenda and Zepbound labels.
Zepbound and birth control pills: its label, sections 7.2 and 8.3, advises people using oral hormonal contraception to switch to a non-oral method or add a barrier method for four weeks after starting Zepbound and four weeks after each dose increase. Discuss this plan with your clinician. This specific instruction should not be transferred to Saxenda.
Read your product's full Medication Guide in the Saxenda or Zepbound label. Trouble breathing or swelling of the face or throat requires emergency help; call 911 in the U.S. Severe or persistent abdominal pain needs prompt medical assessment.
An appointment worksheet you can actually use
Copy these rows into a note. Write “not confirmed” where information is missing, and identify who will resolve it.
| Topic | Bring or write down | Question to resolve |
|---|---|---|
| Goals and medical history | What you want to improve, current diagnoses and relevant history | Which treatment goal are we addressing, and what in my history changes the options? |
| Previous medicines | Exact names, approximate dates, benefits, symptoms and reason for stopping | How does that experience affect the proposed plan? |
| Current medicines | Prescription medicines, nonprescription products, supplements and contraception | What interactions or monitoring need attention? |
| Presentation | Exact prescribed product and device; pharmacy confirmation | Which presentation will I receive, what supplies are needed, and who trains me? |
| Coverage | Plan name, dated benefit response, authorization requirements and quoted personal cost | Is this exact medicine covered for my diagnosis, and what remains unconfirmed? |
| Supply and continuity | Pharmacy stock response, refill outlook and prescriber contact | Given the Saxenda notice, how will we plan ongoing treatment if supply changes? |
| Follow-up | Clinician contact, review date and written symptom instructions | Who checks progress and tolerability, and how do I reach them between visits? |
Keep insurer confirmation and pharmacy stock confirmation as separate answers. A label-listed device does not establish local availability or your price. For a detailed quote checklist, use the Zepbound cost guide.
Before leaving the visit, ask for a written plan naming the chosen product, the reason for the choice, follow-up and whom to contact. If you are changing medicines, request product-specific directions from your prescriber. Do not use this comparison as a switching or injection guide.
Educational information only, not individual medical advice. Labels, coverage and availability can change. Decisions about prescription treatment belong with your licensed prescriber.
Frequently Asked Questions
Is Saxenda being discontinued?
Novo Nordisk says its final Saxenda shipments to wholesalers are planned for late January 2027. It attributes the decision to its portfolio strategy, unrelated to safety or quality concerns. Ask your pharmacy about current stock and your prescriber about treatment continuity. See the manufacturer notice.
Can you take Saxenda and Zepbound together?
Zepbound's label does not recommend combining it with a GLP-1 receptor agonist, which includes Saxenda. Ask your prescriber about your treatment plan. See Zepbound section 1.
Does Zepbound have an approved sleep apnea use?
Yes, for moderate-to-severe obstructive sleep apnea in adults with obesity, together with diet and activity changes. Saxenda has no such indication. See the FDA approval and Saxenda section 1.
Does either medicine have a birth control pill precaution?
Zepbound has a specific oral hormonal contraception precaution. Review the timing and alternatives with your clinician; this instruction is not a shared rule for both medicines. See Zepbound sections 7.2 and 8.3.
Sources
This article is based on the following primary sources. Links open the original documents.
- 1.Saxenda prescribing information, revised February 2026, boxed warning, sections 1–5, 7, 8.1 and 12.1, and Medication Guide · Novo Nordisk · accessed
- 2.Zepbound prescribing information, revised August 2026, boxed warning and sections 1–5, 7.2, 8.1, 8.3 and 12.1 · Eli Lilly and Company · accessed
- 3.FDA approves Zepbound for obstructive sleep apnea in adults with obesity, December 20, 2024 · U.S. Food and Drug Administration · accessed
- 4.Saxenda U.S. manufacturer discontinuation notice: final wholesaler shipments planned for late January 2027; current adult patient information · Novo Nordisk · accessed
Telehealth prescribing rules differ by state. Read the state-by-state guide.
Majesta Health articles are written against primary sources (FDA labeling, NIH and CDC publications, state statutes) and each one passes a documented compliance review before publication. Where an article cites external sources, they are listed at the end of that article so you can check them yourself. No article currently carries an individual physician review; when a physician reviews an article, that page will show the reviewer's name, NPI and review date.
- Written against primary sources: FDA labeling and safety communications, NIH and CDC publications, state statutes and medical board rules
- Documented compliance review against FDA, FTC and LegitScript requirements before publication
- External sources, where an article cites them, are listed at the end of that article with links to the original documents
- Compounded medications are described as not FDA-approved as final products on every page that mentions them